-DOCSTART- -X- O
Yersinia -X- _ B-Patient
pestis -X- _ I-Patient
is -X- _ O
the -X- _ O
etiologic -X- _ O
agent -X- _ O
of -X- _ O
plague -X- _ O
that -X- _ O
has -X- _ O
killed -X- _ O
more -X- _ O
than -X- _ O
200 -X- _ O
million -X- _ O
people -X- _ O
throughout -X- _ O
the -X- _ O
recorded -X- _ O
history -X- _ O
of -X- _ O
mankind. -X- _ O
Antibiotics -X- _ O
may -X- _ O
provide -X- _ O
little -X- _ O
immediate -X- _ O
relief -X- _ O
to -X- _ O
patients -X- _ O
who -X- _ O
have -X- _ O
a -X- _ O
high -X- _ O
bacteremia -X- _ O
or -X- _ O
to -X- _ O
patients -X- _ O
infected -X- _ O
with -X- _ O
an -X- _ O
antibiotic -X- _ O
resistant -X- _ O
strain -X- _ O
of -X- _ O
plague. -X- _ O
Two -X- _ O
virulent -X- _ O
factors -X- _ O
of -X- _ O
Y. -X- _ O
pestis -X- _ O
are -X- _ O
the -X- _ O
capsid -X- _ O
F1 -X- _ O
protein -X- _ O
and -X- _ O
the -X- _ O
low-calcium -X- _ O
response -X- _ O
( -X- _ O
Lcr -X- _ O
) -X- _ O
V-protein -X- _ O
or -X- _ O
V-antigen -X- _ O
that -X- _ O
have -X- _ O
been -X- _ O
proven -X- _ O
to -X- _ O
be -X- _ O
the -X- _ O
targets -X- _ O
for -X- _ O
both -X- _ O
active -X- _ O
and -X- _ O
passive -X- _ O
immunization. -X- _ O
There -X- _ O
are -X- _ O
mouse -X- _ O
monoclonal -X- _ O
antibodies -X- _ O
( -X- _ O
mAbs -X- _ O
) -X- _ O
against -X- _ O
the -X- _ O
F1- -X- _ O
and -X- _ O
V-antigens -X- _ O
that -X- _ O
can -X- _ O
passively -X- _ O
protect -X- _ O
mice -X- _ O
in -X- _ O
a -X- _ O
murine -X- _ O
model -X- _ O
of -X- _ O
plague -X- _ O
; -X- _ O
however -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
anti-Yersinia -X- _ O
pestis -X- _ O
monoclonal -X- _ O
antibodies -X- _ O
available -X- _ O
for -X- _ O
prophylactic -X- _ O
or -X- _ O
therapeutic -X- _ O
treatment -X- _ O
in -X- _ O
humans. -X- _ O
We -X- _ O
identified -X- _ O
one -X- _ B-Intervention
anti-F1-specific -X- _ I-Intervention
human -X- _ I-Intervention
mAb -X- _ I-Intervention
( -X- _ I-Intervention
m252 -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
two -X- _ I-Intervention
anti-V-specific -X- _ I-Intervention
human -X- _ I-Intervention
mAb -X- _ I-Intervention
( -X- _ I-Intervention
m253 -X- _ I-Intervention
, -X- _ I-Intervention
m254 -X- _ I-Intervention
) -X- _ I-Intervention
by -X- _ O
panning -X- _ O
a -X- _ O
na√Øve -X- _ O
phage-displayed -X- _ O
Fab -X- _ O
library -X- _ O
against -X- _ O
the -X- _ O
F1- -X- _ O
and -X- _ O
V-antigens. -X- _ O
The -X- _ O
Fabs -X- _ O
were -X- _ O
converted -X- _ O
to -X- _ O
IgG1s -X- _ O
and -X- _ O
their -X- _ O
binding -X- _ O
and -X- _ O
protective -X- _ O
activities -X- _ O
were -X- _ O
evaluated. -X- _ O
M252 -X- _ O
bound -X- _ O
weakly -X- _ O
to -X- _ O
peptides -X- _ O
located -X- _ O
at -X- _ O
the -X- _ O
F1 -X- _ O
N-terminus -X- _ O
where -X- _ O
a -X- _ O
protective -X- _ O
mouse -X- _ O
anti-F1 -X- _ O
mAb -X- _ O
also -X- _ O
binds. -X- _ O
M253 -X- _ B-Outcome
bound -X- _ I-Outcome
strongly -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
V-antigen -X- _ I-Outcome
peptide -X- _ I-Outcome
indicating -X- _ I-Outcome
a -X- _ I-Outcome
linear -X- _ I-Outcome
epitope -X- _ I-Outcome
; -X- _ I-Outcome
m254 -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
bind -X- _ I-Outcome
to -X- _ I-Outcome
any -X- _ I-Outcome
peptide -X- _ I-Outcome
from -X- _ I-Outcome
a -X- _ I-Outcome
panel -X- _ I-Outcome
of -X- _ I-Outcome
53 -X- _ I-Outcome
peptides -X- _ I-Outcome
suggesting -X- _ I-Outcome
that -X- _ I-Outcome
its -X- _ I-Outcome
epitope -X- _ I-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
conformational. -X- _ I-Outcome
M252 -X- _ I-Outcome
showed -X- _ I-Outcome
better -X- _ I-Outcome
protection -X- _ I-Outcome
than -X- _ I-Outcome
m253 -X- _ I-Outcome
and -X- _ I-Outcome
m254 -X- _ I-Outcome
against -X- _ I-Outcome
a -X- _ I-Outcome
Y -X- _ I-Outcome
, -X- _ I-Outcome
pestis -X- _ I-Outcome
challenge -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
plague -X- _ I-Outcome
mouse -X- _ I-Outcome
model. -X- _ I-Outcome
A -X- _ I-Outcome
synergistic -X- _ I-Outcome
effect -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
when -X- _ I-Outcome
the -X- _ I-Outcome
three -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
combined. -X- _ I-Outcome
Incomplete -X- _ I-Outcome
to -X- _ I-Outcome
complete -X- _ I-Outcome
protection -X- _ I-Outcome
was -X- _ I-Outcome
achieved -X- _ I-Outcome
when -X- _ I-Outcome
m252 -X- _ I-Outcome
was -X- _ I-Outcome
given -X- _ I-Outcome
at -X- _ I-Outcome
different -X- _ I-Outcome
times -X- _ I-Outcome
post- -X- _ I-Outcome
challenge. -X- _ I-Outcome
These -X- _ O
antibodies -X- _ O
can -X- _ O
be -X- _ O
further -X- _ O
studied -X- _ O
to -X- _ O
determine -X- _ O
their -X- _ O
potential -X- _ O
as -X- _ O
therapeutics -X- _ O
or -X- _ O
prophylactics -X- _ O
in -X- _ O
Y. -X- _ O
pestis -X- _ O
infection -X- _ O
in -X- _ O
humans -X- _ O
. -X- _ O

